Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of α2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis

M. Udvardy, D. Schwartzott, K. Jackson, P. A. McKee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The aim of this study was to synthesize and investigate hybrid peptides which contain the RGD (Arg-Gly-Asp) sequence coupled with lysine residues in special arrangements (antiplasmin carboxyterminal peptide) in an effort to simultaneously inhibit platelet aggregation and promote fibrinolysis. The in vitro haemostatic modifying properties of the synthesized peptides were tested by ADP-induced platelet aggregation, plasmin-generation tests and fibrin-clot lysis assays. The hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxyterminal part of antiplasmin (AP26) inhibited platelet activation and increased plasmin generation and in vitro fibrin-clot lysis.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalBlood Coagulation and Fibrinolysis
Volume6
Issue number1
Publication statusPublished - 1995

Fingerprint

arginyl-glycyl-aspartyl-phenylalanine
Antifibrinolytic Agents
Fibrinolysis
Platelet Aggregation
Peptides
Fibrinolysin
Fibrin
Platelet Activation
Hemostatics
Adenosine Diphosphate
Lysine

Keywords

  • antiplasmin
  • antithrombotic effects
  • fibrinolysis
  • platelet aggregation
  • RGD peptides

ASJC Scopus subject areas

  • Hematology

Cite this

@article{459714eda57245d3b35cc9392a8398fa,
title = "Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of α2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis",
abstract = "The aim of this study was to synthesize and investigate hybrid peptides which contain the RGD (Arg-Gly-Asp) sequence coupled with lysine residues in special arrangements (antiplasmin carboxyterminal peptide) in an effort to simultaneously inhibit platelet aggregation and promote fibrinolysis. The in vitro haemostatic modifying properties of the synthesized peptides were tested by ADP-induced platelet aggregation, plasmin-generation tests and fibrin-clot lysis assays. The hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxyterminal part of antiplasmin (AP26) inhibited platelet activation and increased plasmin generation and in vitro fibrin-clot lysis.",
keywords = "antiplasmin, antithrombotic effects, fibrinolysis, platelet aggregation, RGD peptides",
author = "M. Udvardy and D. Schwartzott and K. Jackson and McKee, {P. A.}",
year = "1995",
language = "English",
volume = "6",
pages = "11--16",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of α2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis

AU - Udvardy, M.

AU - Schwartzott, D.

AU - Jackson, K.

AU - McKee, P. A.

PY - 1995

Y1 - 1995

N2 - The aim of this study was to synthesize and investigate hybrid peptides which contain the RGD (Arg-Gly-Asp) sequence coupled with lysine residues in special arrangements (antiplasmin carboxyterminal peptide) in an effort to simultaneously inhibit platelet aggregation and promote fibrinolysis. The in vitro haemostatic modifying properties of the synthesized peptides were tested by ADP-induced platelet aggregation, plasmin-generation tests and fibrin-clot lysis assays. The hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxyterminal part of antiplasmin (AP26) inhibited platelet activation and increased plasmin generation and in vitro fibrin-clot lysis.

AB - The aim of this study was to synthesize and investigate hybrid peptides which contain the RGD (Arg-Gly-Asp) sequence coupled with lysine residues in special arrangements (antiplasmin carboxyterminal peptide) in an effort to simultaneously inhibit platelet aggregation and promote fibrinolysis. The in vitro haemostatic modifying properties of the synthesized peptides were tested by ADP-induced platelet aggregation, plasmin-generation tests and fibrin-clot lysis assays. The hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxyterminal part of antiplasmin (AP26) inhibited platelet activation and increased plasmin generation and in vitro fibrin-clot lysis.

KW - antiplasmin

KW - antithrombotic effects

KW - fibrinolysis

KW - platelet aggregation

KW - RGD peptides

UR - http://www.scopus.com/inward/record.url?scp=0028923122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028923122&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 11

EP - 16

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 1

ER -